HEMNOS clinical trials at UCSF
1 research study open to eligible people
Hemnos uses special immune cells to target cancer. UCSF is researching the use of T cells in children with specific liver cancers to check their safety and tolerance. Scientists are testing how these cells can support cancer treatment.
Showing trials for
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
open to eligible people ages 1-21
Open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety/tolerability and determine the recommended Phase II Dose (RP2D) of ET140203 T-cells in pediatric subjects who are AFP-positive/HLA-A2-positive and have relapsed/refractory HB, HCN-NOS, or HCC.
San Francisco, California and other locations
Our lead scientists for HEMNOS research studies include Arun Rangaswami, MD.
Last updated: